Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target lifted by analysts at Piper Sandler from $80.00 to $90.00 in a report released on Tuesday, Marketbeat Ratings reports. The firm presently has a “neutral” rating on the medical research company’s stock. Piper Sandler’s target price indicates a potential upside of 9.44% from the stock’s current price.
A number of other research analysts have also recently weighed in on the stock. UBS Group assumed coverage on shares of Exact Sciences in a report on Friday, May 5th. They issued a “neutral” rating and a $73.00 price objective for the company. Credit Suisse Group lifted their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Bank of America lifted their price objective on shares of Exact Sciences from $105.00 to $110.00 in a report on Wednesday, August 2nd. Stifel Nicolaus lifted their price objective on shares of Exact Sciences from $85.00 to $120.00 in a report on Thursday, June 22nd. Finally, Benchmark cut shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.00.
Check Out Our Latest Report on Exact Sciences
Exact Sciences Trading Down 2.7 %
Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its earnings results on Tuesday, August 1st. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.05. Exact Sciences had a negative net margin of 18.76% and a negative return on equity of 14.08%. The firm had revenue of $622.10 million during the quarter, compared to analysts’ expectations of $601.14 million. During the same quarter last year, the company posted ($0.94) earnings per share. The firm’s revenue was up 19.3% compared to the same quarter last year. Equities research analysts predict that Exact Sciences will post -1.94 earnings per share for the current year.
Insider Buying and Selling
In other Exact Sciences news, insider Brian Baranick sold 1,350 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $85.04, for a total value of $114,804.00. Following the transaction, the insider now directly owns 8,871 shares in the company, valued at approximately $754,389.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Exact Sciences news, insider Brian Baranick sold 1,350 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $85.04, for a total value of $114,804.00. Following the transaction, the insider now directly owns 8,871 shares in the company, valued at approximately $754,389.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James Herriott sold 1,300 shares of the business’s stock in a transaction dated Thursday, June 8th. The shares were sold at an average price of $90.00, for a total transaction of $117,000.00. Following the completion of the transaction, the general counsel now owns 7,264 shares in the company, valued at $653,760. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,352 shares of company stock worth $683,539. 1.30% of the stock is owned by insiders.
Hedge Funds Weigh In On Exact Sciences
Several large investors have recently made changes to their positions in EXAS. Park Place Capital Corp lifted its holdings in shares of Exact Sciences by 189.2% in the 1st quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after acquiring an additional 246 shares during the last quarter. Desjardins Global Asset Management Inc. lifted its holdings in shares of Exact Sciences by 42.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 549 shares of the medical research company’s stock worth $27,000 after acquiring an additional 163 shares during the last quarter. True Wealth Design LLC acquired a new position in shares of Exact Sciences in the 4th quarter worth approximately $30,000. Assetmark Inc. acquired a new position in shares of Exact Sciences in the 4th quarter worth approximately $31,000. Finally, TCI Wealth Advisors Inc. lifted its holdings in shares of Exact Sciences by 15,466.7% in the 1st quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after acquiring an additional 464 shares during the last quarter. 90.25% of the stock is currently owned by institutional investors and hedge funds.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
- Five stocks we like better than Exact Sciences
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Best Renewable Energy Stocks as Summer Heat Builds
- How and Why to Invest in Oil Stocks
- Kinder Morgan Shines With Dividend Yield, Cash Flow, Buybacks
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks to Buy No Matter Which Way Inflation Moves
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
